Clinical trials in severe sepsis with drotrecogin alfa (activated).

Crit Care · 2007 · PMC2230609 · PMID 18269692

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The 1-year and 2.5-year follow up by Angus and coworkers [ 10 ], which was not adequately powered to evaluate a survival endpoint, identified a nonsignificant benefit in patients treated with DrotAA in the overall population but a highly significant benefit in patients with baseline APACHE II score greater than 24.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.